Scancell is a late-stage clinical oncology specialist developing novel, “off-the-shelf” active immunotherapies. The investment case is being transformed by an elegant dual NASDAQ/AIM listing and comprehensive funding package. Following a multi-step acquisition and financing package, the iSCIB1+ programme is now fully funded to enter its global, c 550-patient registrational Phase III study in late-2026. This complex series of actions removes historical UK capital overhangs and extends the cash runway into 2029. Importantly, accessing the deep US life sciences capital pools ensures long-term support for all the promising pipeline programmes. Near-term catalysts remain plentiful, including maturing Phase II SCOPE data, interim ModiFY synergy updates, and potential milestone payments from the GlyMab antibody portfolio. Our updated rNPV valuation for Scancell is £408m ($530m), equivalent to 34p/share.
| Year-end: April 30 | 2024 | 2025 | 2026E | 2027E |
| Revenues (£m) | 0.0 | 4.7 | 0.0 | 2.3 |
| EBITDA (£m) | (17.3) | (14.1) | (18.4) | (28.4) |
| PBT (£m) | (9.1) | (15.3) | (20.7) | (30.1) |
| Net Income (£m) | (5.9) | (12.3) | (19.2) | (27.9) |
| EPS (p) | (0.68) | (1.26) | (1.85) | (2.48)* |
| Cash (£m) | 14.8 | 16.9 | 1.9 | (3.3) |
Update
6 October 2026
| Price | 9.40p |
| Market Cap | £127.5m |
| Enterprise Value | £110.7m |
| Shares in issue | 1,212.2m |
| 12 month range | 7.26-29.50p |
| Free float | 56.5% |
| Primary exchange | AIM London |
| Other exchanges | N/A |
| Sector | Healthcare |
| Company Code | SCLP.L |
| Corporate client | Yes |
Company description
Scancell is a clinical-stage immuno-oncology specialist. The key value drivers are iSCIB1+, the lead ImmunoBody programme, and Modi-1, the lead Moditope programme. The novel GlyMab glycan antibodies are earlier in development.
Analysts
Lala Gregorek
lgregorek@trinitydelta.org
+44 (0) 20 3637 5043
Franc Gregori
fgregori@trinitydelta.org
+44 20 3637 5041
Table of Contents
Scancell is a clinical-stage oncology specialist developing immunotherapies. Its investment case has been transformed by the dual NASDAQ/AIM listing and comprehensive funding package currently underway. Its differentiated portfolio is anchored around two novel ‘off-the-shelf’ platforms, ImmunoBody and Moditope, complemented by the GlyMab antibody platform. Following a complex acquisition and financing arrangement, the lead iSCIB1+ programme will now be fully funded to enter its global c 550-patient registrational Phase III study in late-2026. This removes historical capital overhangs, extending the cash runway into 2029 while accessing the deep US life sciences capital pools allows support for all platform progression. Near-term catalysts remain plentiful: iSCIB1+ SCOPE Phase II data continues to mature ahead of calendar H127 updates, interim ModiFY data will clarify lead asset Modi-1’s synergy with checkpoint inhibitors, and the GlyMab portfolio is positioned to trigger milestone payments upon clinical entry. Our rNPV valuation is £408m, or 34p/share, with further upside potential as development visibility increases.
Scancell is part-way through a series of carefully orchestrated corporate actions that will transform the business. The goal is to create a well-funded dual NASDAQ and AIM listed entity that can progress its promising lead asset, iSCIB1+, through to interim data in its registrational Phase III trial. The outcome will be a pro-forma net cash balance of c £59.2m (c $79.1m) before costs, and a cash runway that extends beyond the pivotal iSCIB1+ clinical read-out scheduled for calendar H228. The complexity of the transactions reflects the reality of the structural limitations faced by AIM listed companies when their lead asset(s) successfully progress through the later stages of clinical development. These capital constraints are not new and are well documented (Bleeding to death: the science and technology growth emergency), yet a lack of timely political and regulatory action means proactive managements have little choice but to cross the Atlantic.
The transaction architecture (Exhibit 1) deliberately combines the acquisition of a NASDAQ-listed cash shell, a planned US private equity placement (PIPE), a flexible non-dilutive debt instrument, and a UK institutional placement and retail offer to allow local investors to maintain their positions (and benefit from the pricing discount). It is worth dissecting the anatomy of the deals as this is not merely a capital raising exercise, and each transaction fulfils a distinct and complementary role in this pathway to a NASDAQ listing.
The first step sees Scancell acquire Neuphoria Therapeutics Inc (NASDAQ: NEUP) in an all-share “reverse merger” transaction whereby Scancell shareholders own 85.5% and Neuphoria shareholders 14.5% of the combined company on a pro forma basis. On closing, expected late Q426/early Q127, each Neuphoria share will convert into 37.77 Scancell ADSs (1 ADS = 10 ordinary shares) and a non-transferable CVR (contingent value right) connected to any potential future net proceeds from Neuphoria’s partnered assets. The enlarged entity will then continue trading as Scancell (with Neuphoria an indirect wholly owned subsidiary) and maintain its AIM listing, while also establishing a NASDAQ Level 3 ADS (ticker: SCLT).
The role of the CVRs is to allow existing Neuphoria holders to benefit from any potential upside in the legacy assets although, realistically, the likelihood is acknowledged as being low. The CVRs also, indirectly, ensure Scancell’s core oncology portfolio is insulated from Neuphoria’s historical activities.
In October 2025 Neuphoria’s lead asset BNC210, an oral negative modulator of alpha-7 nicotinic acetylcholine receptor (α7-nAChR) for anxiety, failed in the Phase III AFFIRM-1 trial for Social Anxiety Disorder (SAD). Subsequently, partner MSD (Merck Sharp & Dohme) conducted a pre-specified interim analysis on MK-1167, a positive modulator of α7-nAChR that was in a Merck-funded Phase II study for Alzheimer’s, and found it too had failed to meet the efficacy threshold. Two early-stage monoclonal antibody programme targeting cancer stem cells (BNC101 and BNC105) were previously out-licensed to Carina Biotech.
A more promising, although admittedly small, legacy upside rests within the 4.65% holding Neuphoria, then known as Bionomics, had in the Australian CTx CRC consortium with the programme involving small-molecule inhibitors targeting KAT6A and KAT6B lysine acetyltransferases. Pfizer bought the global exclusive rights and it is progressing though Phase III combination and Phase I monotherapy trials in HR+/HER2- metastatic breast cancer. The CVRs have been deliberately fixed at 15 years from deal closure to allow for the Merck and Pfizer partnerships to be given an appropriate multi-year runway to mature fully.
Neuphoria’s strategic review, initiated in December 2025, slashed its operations and minimised its cost base to become effectively a cash shell. This troubled period, during which activist shareholder Lynx1 Master Fund launched a short-lived hostile bid, resulted in a market cap averaging c $21m, with a high of $25.7m and a low of $15.7m. This suggested an underlying, net of forecast cash, valuation for a clean NASDAQ listing of $11m, at the lower end of the $12m to $15m that is anecdotally attributed to an unencumbered shell in the biotech space.
Scancell announced on July 23, 2026, that it was acquiring Neuphoria in an all-share transaction for 204.14m new ordinary shares (equivalent to 20.41m ADS) priced at 9p per share (or $12.05 cents), the same as the rest of the equity raise elements). Based on current assumptions and reflecting the 10:1 share consolidation planned to be effective on October 21, this would mean issuance of 20.4m consideration shares to Neuphoria shareholders. The deal is conditional on a minimum of $10m in cash being transferred at close. This values the acquisition at c $24.6m and implies Scancell is paying c $14.6m (albeit in shares not cash) for this NASDAQ listing.
The merits of a NASDAQ listing for Scancell are, in our view, clear. An oncology pioneer such as Scancell cannot rely solely on UK capital to fund a global, registrational Phase III trial; the specialised healthcare funds that have the multi-billion-dollar resources and technical expertise necessary to value and support late-stage immunotherapy platforms are largely in the US and are reluctant to invest in AIM stocks; and, whilst a NASDAQ listing is not a panacea for all corporate and financing ills, history repeatedly shows partnering transactions (especially with US majors) have greater likelihood of completing for companies with the visibility and credibility that accompanies being on NASDAQ.
If the premise of the need to migrate to a dual listing is accepted, then the question becomes which route is better. There are pros and cons to both principal pathways, with the key features examined in Exhibit 2. While a traditional IPO remains the gold standard for well-capitalised US biotechs with deep domestic ties, it represents a lengthy, costly, and executive-draining path for foreign, smaller entities, luxuries that European clinical-stage companies with tight capital runways can ill afford. For an asset-rich but capital-constrained company like Scancell, the cash shell acquisition route offers a viable alternative. By merging into an existing, compliant NASDAQ vehicle, Scancell circumvents the public roadshow, caps its transaction expenses in equity rather than cash, and accelerates its listing timeline. We would argue the cash shell alternative provides Scancell with a safer, faster, and more cost-effective entry onto the global stage.
The first step in securing the funding for iSCIB1+ was the domestic capital raise. This was structured as a parallel UK institutional placing and a retail offer, initially targeting £9.0m and up to £2.3m respectively. Although totally separate from the US PIPE, the placement and offer should be viewed in the context of the larger planned US transactions, explaining the pricing framework that was established across all tranches. Scancell’s largest institutional insiders, Redmile Group and Vulpes Investment Management, did not participate in this placing, with their capital commitment directed into the conditional US PIPE tranche.
Panmure Liberum and WG Partners addressed UK institutional investors with strong demand resulting in an oversubscribed book partially satisfied through upsizing the raise to £13.0m. Shares were intentionally placed with long-standing shareholders, allowing them to maintain their positions on equivalent terms as the US PIPE investors, although several select new investors were brought on board.
The retail offer had to meet similarly tight timelines and used the Winterflood Retail Access Platform (WRAP). This route allowed investors to apply for shares through their existing stockbrokers as normal. As total applications exceeded the initial £2.3m limit, the retail tranche was upsized to £2.7m, with final allocations scaled back to ensure a fair distribution across the existing retail base. This brought the total raised to £15.7m (gross) which, not being contingent on either the Neuphoria acquisition or the PIPE raise, immediately secures Scancell’s cash runway to Q2 calendar 2027 and allows management to plan the Phase III study whilst legal and regulatory processes for the acquisition and PIPE are underway.
Scancell has sought to minimise shareholder dilution through using debt in combination with the equity raises. To understand how this non-dilutive portion of the capital programme works, the $25m (c £18.7m) senior secured debt facility with various Blackrock managed funds should be viewed chronologically. The loan facility is structured into four tranches, separating immediate working capital from the later conditions of the US transactions:
Each debt tranche includes an initial 18-month interest-only period, followed by standard repayment of principal and interest. There is also a warrant facility with Kreos Capital, a Blackrock affiliate, which will be pro rata to actual amounts drawn down. The number of ordinary shares issued at warrant exercise will be equal to 4.5% of the amount borrowed (ie $1.15m) priced at 9p per share (the pricing of the PIPE) or, if this does not complete, the lower of the price paid in any future equity financing or the 30-day VWAP following announcement that the PIPE will not complete. Warrants are exercisable up to 10 years from grant or on sale of the company. The debt financing (including draw down and warrant issue) is subject to shareholder approval at the EGM, and we note that all pricing remains subject to adjustment for the share consolidation.
The cornerstone of the capital programme is a conditional $39.1m (c £29.2m) US Private Investment in Public Equity (PIPE). Unlike the UK placing, the PIPE is contingent upon the formal closing of the Neuphoria acquisition. The transaction is engineered to settle simultaneously, planned for late calendar Q426/early Q127 but acknowledging that delays can occur. The whole package is designed to satisfy the numerous NASDAQ listing conditions, including financial and price regulations (eg a $4.00 minimum bid price) and liquidity and distribution rules (eg a minimum of 300 to 450 public shareholders holding 100+ shares and at least three market makers).
The PIPE is underpinned by Scancell’s two largest existing shareholders, Redmile Group and Vulpes Investment Management, who continue to demonstrate their unstinting support. Additional new, accredited, shareholders are known to have expressed interest in taking part in the US element of the equity raise. Leerink Partners, TD Cowen, and HC Wainwright & Co are acting as placement agents.
By placing this new capital within a US-regulated vehicle, these funds seed and enable the incoming NASDAQ Level 3 ADS line from day one. This provides an immediate institutional depth on the US listing without forcing management to be reliant on targeting investors through a series of roadshows.
The placement is priced at $0.1205 per ordinary share equivalent, which matches the 9.0p per share established in the UK. This was the requirement to secure the US capital and, once the US investors set the $0.1205 pricing floor, UK securities laws required Scancell to offer identical terms to its domestic shareholders.
Alongside the new cash investment, Redmile will convert its entire outstanding Convertible Loan Note (CLN) balance into non-voting new ordinary shares (or ADS equivalents), adjusted for dilutive financing impact. This removes the company’s primary legacy debt overhang, allowing Scancell to present a clean, unencumbered balance sheet to the US market at closing.
To accommodate the scale of Redmile’s combined cash injection and CLN conversion, a significant portion of their new equity will be issued as non-voting ordinary shares (or restricted ADSs). This is a technical mechanism that allows Redmile to maintain its financial backing of the global iSCIB1+ Phase III trial without breaching the 30% takeover threshold mandated by the UK Takeover Code. Post-completion Redmile intends to hold <10% of the voting share capital.
The pathway to completion requires navigating a series of concurrent corporate, investor, and regulatory clearances across both UK and US jurisdictions. As the initial UK capital injection has been successfully accomplished, the checklist now shifts to closing of the acquisition, implementation of the NASDAQ listing, and trigger of the remaining capital inflows. The immediate timeline and core hurdles are as follows:
Management is currently tracking a definitive transaction close in late calendar Q426/early Q127. There is a back stop of 28 February 2027 (end date), which may be extended by a further 60 days if the SEC has not yet declared the F-4 effective. As mentioned previously, by uncoupling the UK placement/offer from these final steps, Scancell’s development team is fully funded to advance early Phase III prep-work, while the corporate legal teams work to clear these regulatory gates over the coming months.
Scancell’s lead asset, iSCIB1+, is completing the Phase II SCOPE study of SCIB1/iSCIB1+ in combination with doublet checkpoint inhibitors (Yervoy [ipilimumab] plus Opdivo [nivolumab]) in advanced melanoma. SCOPE’s primary aim is to demonstrate that SCIB1/iSCIB1+ in combination with CPI doublet therapy acts synergistically and achieves improved clinical outcomes. The data to date have been detailed previously (November 2025 Outlook) and indicate that the iSCIB1+ construct elicits broad, potent and specific immune responses, with a clean safety profile and no unexpected toxicities.
The latest data confirm progression-free survival (PFS) in the target HLA population of 77% at 22 months. This compares with a reported PFS of 43% at 22 months for ipilimumab plus nivolumab alone, the current standard of care. For context, the median PFS of 11.5 months achieved by the CPI doublet in the CheckMate-067 trial is the highest observed in such advanced melanomas, with a median PFS of 7.9 months from real-world data. Further PFS and early overall survival (OS) data from SCOPE are expected to report in calendar H127.
These data have supported positive interactions with the FDA, with IND clearance in January 2026 for the Phase III trial of iSCIB1+ (plus doublet CPI) in advanced melanoma (Exhibit 3). This was expanded with the grant of Fast Track Designation (FTD) in April 2026, which acknowledges the unmet medical need in advanced melanoma and allows for frequent engagement with regulators, alongside the potential for rolling reviews of future regulatory submissions. FDA agreement on the proposed trial design should smooth the path for ongoing discussions with the EMA in Europe and other key regulators. MHRA clinical trial approval was granted in the UK in August 2026.
The FDA grants expedited pathways to investigational therapies where the preliminary clinical data show a substantial improvement over existing standard of care options. Aside from the confirmation of the perceived clinical value it conveys, the FTD allows for accelerated approval based on PFS data, with the full approval typically given when the OS data has matured. For Scancell this translates not simply into potentially quicker and more predictable timelines, but it should reduce the uncertainties inherent in regulatory approvals.
The iSCIB1+ registrational study design will involve c 550 patients with stage III/IV unresectable melanoma in a two-arm design that has 1:1 randomisation to standard of care (ipilimumab + nivolumab) with or without iSCIB1+ (c 275 patients in each). The trial is a multi-centre, double-blinded study spanning c 90 centres across the US (most likely the majority), UK, and Europe. As established in SCOPE, the target population includes HLA haplotypes A2, A3, A31, B35, B44, and Bw4, and excludes acral melanoma and active brain metastases. The dose is confirmed as 8mg intramuscularly, with up to eleven weekly doses. The trial has an adaptive design and there is an option for the patient numbers to be increased.
The primary efficacy endpoint is PFS (Progression Free Survival), a survival endpoint increasingly favoured by regulators as it provides a clear and meaningful measure of real patient benefit. A secondary endpoint of OS (Overall Survival), which is still viewed by many as the “gold standard” benchmark, will also be assessed. The study incorporates a pre-specified data read-out after a certain number of expected PFS events, that should be at around month 24, which could have a 90% statistical power and support an accelerated approval. Assuming the first patient enrolment is before end-2026, and recruitment remains uneventful, the interim PFS should be available in H228.
The trial has a further pre-specified read out of OS events, which in our view could occur around month 48, ie H230, and that would support full approval. The follow-up element would continue, monitoring OS to completion. Our launch assumptions and clinical ramp-up reflect this indicative timeline, with our conservative forecasts based on uptake increasing materially leading up to and following full approval (this should overlap with regulatory and reimbursement approvals across other major markets).
The appointment of an experienced and proven CRO (Contract Research Organisation) is an important step in taking iSCIB1+ into a complex and multi-geography clinical trial. Such a specialist partner can rapidly establish the heavy background infrastructure, such as data networks and safety monitoring, needed to ensure its smooth running and clear the administrative hurdles quickly so that the selected sites can be signed up promptly. The financial markets view the enrolment of the first patient as a major de-risking event as it typically signifies the appropriate funding is in place and the medical institutions are comfortable placing their patients on the trial.
The iSCIB1+ opportunity is attractive with the potential to shift the standard of care in advanced melanoma if the durable results seen to date are replicated in the registrational trial. This is a directly positive outcome for patients as it means they can live for longer without their disease worsening. There remains an unmet need in this group of patients; despite CPIs improving patient outcomes, only around 50% of patients maintain a long-term benefit, with the remainder either relapsing or becoming refractory to CPI treatment.
More broadly, Scancell has highlighted future upside potential in earlier disease settings such as neoadjuvant/adjuvant resectable melanoma (where additional improvement in outcomes might be achieved given the less frail patient population) or as a preventative therapy in certain high-risk groups.
Our current Scancell valuation and iSCIB1+ peak sales assumption only considers the advanced melanoma indication where there is visibility on the clinical plans and regulatory timelines, but we do note the upside potential for iSCIB1+ in earlier disease settings, such as neoadjuvant/adjuvant resectable melanoma. This is based on activity observed in an earlier Phase I monotherapy study with SCIB1 examining varying doses (ranging from 0.1mg to 8mg) in 35 patients with partially and fully resected stage III/IV melanoma. A striking finding was that all patients were alive at the 39-month cut off and 10 of 16 patients (those on doses >2mg) were disease free at 60 months.
Assuming the current funding programme is secured, management is evaluating the initiation of a Phase II trial (Exhibit 4) in the neoadjuvant (before surgery) and adjuvant (post-surgery) settings in calendar H127. The trial design is expected to evaluate three treatment regimens: Arm 1 with iSCIB1+ as monotherapy; Arm 2 dosing iSCIB1+ in combination with pembrolizumab (Keytruda); Arm 3, effectively the control, with pembrolizumab monotherapy.
We note that topline Phase III readout of the first combination regimen in adjuvant melanoma, Merck/Moderna’s personalised mRNA cancer vaccine, intismeran, in combination with pembrolizumab, recently demonstrated improved EFS. Full results will be presented at a future conference.
The National Institutes of Health estimate there will be c 112k new cases of melanoma in the US in 2026, rising by 2.2% over the near term (the 117k figure of Exhibit 5 used by management as the addressable market by the time of iSCIB1+ potential first approval) and growing by 2%-4% through to 2040. Of these, c 94k cases will present with localised (Stages I & II) or resectable regional (Stage IIIA), where the spread is to a single lymph node (corresponding to the c 98k patient figure below). Stages IIIB to IIID and Stage IV are more severe, where the lesion has broken through the skin or has metastasised. Stage IIIB through to Stage IV collectively represent c 19k patients, of which 80% are eligible for iSCIB1+ treatment due to their HLA status (the c 16k forecast in 2028).
The main five European markets, together with Australia, are expected to have similar populations, with growth rates averaging 4%-5%. The key difference between these patient groups will be the rate of clinical adoption, fastest in the US and probably slowest in the UK, France and Germany, and the degree of pricing power (lowest in the national health services of Europe). Whilst there are understandably many variables, management estimates the global peak sales for iSCIB1+ to be c $3bn in the unresectable and metastatic indications, rising to $6bn to $9bn if iSCIB1+ proves to provide a similar improvement to that seen in the SCOPE study when used in combination with pembrolizumab in the neoadjuvant/adjuvant setting.
At this stage we have not included iSCIB1+ use in these wider settings in our modelling. Whilst we believe our policy of deliberately employing conservative assumptions is appropriate, we also feel that investors should be aware of the potential wider opportunities should iSCIB1 demonstrate efficacy and safety successfully in the forthcoming pivotal Phase III trial and, importantly, the proposed Phase II study in the neoadjuvant/adjuvant setting. Promising progress in these trials are the value inflection points, as success probabilities would rise and market opportunities widen.
With the ImmunoBody platform in the limelight, it is easy to overlook Scancell’s other “off-the-shelf” therapeutic vaccine platform: Moditope, a novel approach that stimulates a cytotoxic CD4 T-cell response. Moditope effectively generates an immune response against cells undergoing autophagy (a vital survival process for most cancer cells) by targeting a modification on proteins. Autophagy is particularly pronounced in the hypoxic core of expanding tumours, prior to angiogenesis and the establishment of new vasculature. During this process, stress-induced post-translational modifications (siPTMs) and proteolytic cleavage generate modified peptides that accumulate at higher levels in tumours compared to normal tissues. Exceptional results have been observed in preclinical studies, and the aim is to replicate these in the current clinical Phase II trial programme.
Modi-1, the lead Moditope programme, is being evaluated in the Phase I/II ModiFY multi-cohort basket study across a range of difficult-to-treat solid tumours as monotherapy and in combination with standard of care checkpoint inhibitors (Exhibit 6). The study is fully recruited with over 120 patients enrolled over 16 sites in the UK. Encouraging early efficacy was seen both as monotherapy and in combination, with good T-cell responses, in various hard-to-treat cancers, including head & neck, ovarian, and triple negative breast cancer. In HPV negative head and neck cancer, three of seven patients saw a partial response at their week 25 scan. The ORR (objective response rate) was 43%, which compares to historical ORRs of 19% for pembrolizumab and 13% for nivolumab.
PFS results from the two Phase II cohorts, exploring Modi-1 in squamous cell cancer of head and neck (SSCHN) in combination with pembrolizumab and in renal cell carcinoma (RCC) in combination with ipilimumab and nivolumab, are expected to be released in calendar 2026. As with iSCIB1+, the combination of Modi-1 with CPIs could be highly synergistic and lead to improved patient outcomes. These Phase II data will inform the development strategy.
GlyMabs are specialised anti-glycan monoclonal antibodies (mAbs) that target tumour-specific sugar motifs rather than proteins. Aberrant glycosylation is a hallmark of many cancers, shaping nearly every stage of tumour initiation, progression, and metastasis. Importantly, these are not random by-products of disordered biosynthesis in malignant cells; rather, they represent precise and reproducible alterations closely associated with transformation and tumour progression. However, tumour-associated glycans are difficult to harness as therapeutic targets and, unlike proteins, they are also less immunogenic, meaning that the immune system generates weak responses against them.
The flexible, consistent, reproducible, and potent GlyMab platform has potentially overcome these limitations. The technology stems from Scancell’s in-house expertise and can be employed to produce many differentiated mAbs that bind selectively to the target tumour-associated glycans. Preclinical studies have shown GlyMabs can achieve high affinity for glycans that are markedly overexpressed on cancer cells.
The initial pipeline of five differentiated antibodies is generating encouraging preclinical data that directly led to Genmab licensing two programmes: SC129 sialyl-di-Lewisa and SC2811 that targets glycolipid stage-specific embryonic antigen 4 which could have clinical value in many solid tumours. Each separate deal carries up to $624m in aggregate milestones across three modalities plus low single digit royalties on net sales. Scancell has so far received an aggregate c $12m in upfront payments, with the next milestone expected to be triggered by the start of clinical trials.
A new company, GlyMab Therapeutics, was formed in 2025 enabling the separation of the vaccine and antibody platforms into independent corporate entities. This potentially offers two independent value creation pathways.
Following the close of the UK placing and retail offer we have updated our Scancell sum-of-the-parts valuation model to £408m ($530m), equivalent to 34p per share (29p fully diluted). However, this will need to be revised on completion of the NASDAQ listing (conditional on the Neuphoria acquisition closing) and linked fund raise (PIPE). Closure of the US financing transactions and drawdown of Tranche 1 of the Blackrock facility would add c $40m (c £30.7m) of net cash to the balance sheet (c $47m from the PIPE and Neuphoria net of $7m of debt). Exhibit 7 provides an overview of our valuation and underlying assumptions.
The key changes to our valuation assumptions include rolling forwards our valuation in time, adjusting the GBP:USD FX rate to 1.3 (from 1.25 previously), and reflecting the impact of the UK funding transactions by including the net proceeds in the current cash balance as well as updating the number of shares outstanding. Note that share count used is based on the current pre-consolidation number of shares and that initially, each ADS will represent 10 ordinary shares; however, subject to shareholder approval at the October EGM, a 10:1 share consolidation (1:1 ADS ratio) will become effective October 21. For context, our prior valuation was £399m ($499m), or 39p per share, with further detail in our June 2026 Update.
iSCIB1+, valued at £210m/$273m, remains the key value driver in our risk-adjusted net present value (rNPV) model, with the next step change on the first patient enrolment into the registrational Phase III trial. This would trigger an uplift from our current 30% success probability based on standard industry rNPV models whereby funded oncology assets with solid Phase II data have probabilities ranging from 50% to 65%. Assuming a conservative 50% probability of success for iSCIB1+, and all else being equal, this would translate into an iSCIB1+ valuation of £350m/$455m, and a £548m/$712m Scancell company valuation, equivalent to 45p per share.
However, the FDA grant of Fast Track Designation (FTD) adds an important element to our success probabilities, as does the reduction in financial uncertainty once the US transactions close in the coming months. For the company a FTD brings benefits such as fewer trial design flaws, rolling reviews (eg pre-vetting of CMC and preclinical modules), and faster approvals (ie a six-month process vs the ten-month standard). FTD is, in itself, not associated with higher probabilities of clinical success at Phase III, but it does improve regulatory approval probability. Consequently, applying a 65% probability, acknowledging the above and the strength of the SCOPE data, coupled with the targeting of suitable HLA patients, would result in an iSCIB1+ valuation of £455m/$592m and a whole company valuation of £653m/$848m, equivalent to 54p per share.
In addition to unwinding the iSCIB1+ risk-adjustment, other sources of potential valuation upside include higher uptake/peak sales and/or development in broader melanoma settings. Our $1.5bn iSCIB1+ peak sales forecast reflects solely the opportunity in advanced melanoma; it does not currently include any contribution for neoadjuvant/adjuvant melanoma or other indications as no specific clinical trials have been initiated. We note that Scancell’s management estimates a >$3bn potential for iSCIB1+ in advanced melanoma alone, hence greater clinical adoption and penetration than our, admittedly conservative assumptions, represents potential for upside to our model. Furthermore, looking beyond this pivotal trial in advanced melanoma patients, as mentioned, the market opportunity increases significantly if iSCIB1+ could be shown to work in the neoadjuvant/adjuvant settings. The next key inflection point is the start of the Phase II study, which is currently scheduled to start in H1 calendar 2027.
Completion of all the new funding transactions secured by Scancell and including the closing cash in Neuphoria would result in anticipated pro forma net cash (before transaction costs) of around $79.1m (c £59.2m), extending the cash runway into 2029, beyond key clinical milestones including, critically, the iSCIB1+ Phase III primary readout in H228. Following the close of the UK placing and retail offer, which raised gross proceeds of £15.7m, Scancell is funded into Q2 calendar 2027. These funds provide both near-term working capital and the resources to support preparation of the iSCIB1+ Phase III trial. The remaining US listing transactions (ie Neuphoria merger, US PIPE, and Blackrock debt facility) are inter-conditional and are expected to close in late Q4 calendar 2026/early Q127.
The precise details of new funding sources are as follows:
Scancell’s UK equity raise and US PIPE will increase the post-consolidation share count by c 17.45m, and additional new ordinary shares (or ADS equivalent) will also be issued in connection with the Neuphoria all share merger (c 20.4m) and the Redmile CLN conversion (c 19.2m). Post completion of all financing transactions, Scancell will have c 193.2m shares in issue.
Scancell has stated that proceeds will be directed towards funding further iSCIB1+ development (principally the registration-enabling Phase III in advanced melanoma, but also the Phase II study in the neoadjuvant/adjuvant setting), the ongoing Phase I/II ModiFY trial in RCC and HNSCC, and for working capital and general corporate purposes. With plans to secure the necessary funding now in place we have updated our FY27 forecasts, which previously reflected illustrative base spend, to incorporate revised cost assumptions.
We maintain a FY27e (year ending 30 April 2027) revenue expectation of c £2.3m in connection with an assumed $3m milestone on the anticipated start of clinical trials for SC129, the first GlyMab partnered with Genmab. However, we note that precise timing of milestone trigger is unpredictable, the quantum of the milestone is undisclosed, and that Genmab controls development progress for partnered GlyMab assets.
As the iSCIB1+ registration study is slated to start before end-calendar 2026 we have increased our FY27e (year ending 30 April 2027) R&D investment to £22.9m (£5m previously) to cover preparatory work and trial initiation, plus ongoing costs associated with the SCOPE and ModiFY studies. For G&A, we continue to forecast costs of £5.1m for FY27e but also include placeholder non-recurring exceptional expenses of £2.5m in relation to the funding transactions.
Updated financial forecasts (Exhibit 9) currently reflect a scenario whereby FY27e cash inflow does not include proceeds from funding transactions yet to close (US PIPE, Neuphoria merger, Blackrock debt facility drawdown). Thus, this illustrates a funding need at end-FY27e (end-April 2027) which will be addressed by the successful close of those transactions. This scenario also assumes that the outstanding CLNs will convert on their respective expiry dates in FY28e.
Last reported cash was £8.6m at end-October 2025. This was subsequently boosted by a £3m R&D tax credit receipt and c £15m net from the UK funding transactions, extending the cash runway into Q2 calendar 2027. Drawdown of the first tranche of the Blackrock facility would further prolong this runway through to mid-2027. The synchronised closing of the US PIPE and Neuphoria acquisition, bringing in a further $39.1m gross and minimum of $10m respectively, coupled with the second debt tranche will provide funding into 2029. This extends beyond key clinical milestones (Exhibit 8) including the iSCIB1+ Phase III primary readout in H228. Nearer-term news flow includes further Modi-1 data from the Phase II ModiFY trial, updates on the progress of iSCIB1+, start of the iSCIB1+ Phase II study in the neoadjuvant/adjuvant setting, plus mature PFS and OS data from the Phase II SCOPE study.
Disclaimer
Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.
ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.
In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.
Any person who is not a relevant person under Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.
This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.
Copyright 2026 Trinity Delta Research Limited. All rights reserved.